Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 33Neoplasms 27Colorectal Neoplasms 20Breast Neoplasms 16Ovarian Neoplasms 15Pancreatic Neoplasms 13Neoplasm Metastasis 12Lung Neoplasms 11Stomach Neoplasms 10Leukemia, Myeloid, Acute 10Melanoma 9Lymphoma, Non-Hodgkin 8Small Cell Lung Carcinoma 6Recurrence 6Liver Neoplasms 6Leukemia 6Head and Neck Neoplasms 6Fallopian Tube Neoplasms 6Prostatic Neoplasms 5Glioblastoma 5Cholangiocarcinoma 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Gastrointestinal Neoplasms 4Uterine Cervical Neoplasms 3

Interventions

tanespimycin 2pembrolizumab 2parsaclisib 2cemiplimab 2Midazolam 2MLN 8237 2Injections 2zanidatamab 1tislelizumab 1spartalizumab 1sitravatinib 1repaglinide 1pemigatinib 1pamiparib 1liposomal doxorubicin 1lenvatinib 1epothilone B 1drospirenone 1cabiralizumab 1Temozolomide 1Pemetrexed 1Paclitaxel 1Nivolumab 1N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1MLN8054 1Ipilimumab 1HMPL-013 1Gemcitabine 1Ethinyl Estradiol 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Malignancies × Drug Therapy × Clear all
NCT06468098 2024-07-18

A Study of IBI363 in Subjects With Advanced Malignancies

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Recruiting
556 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡